David Altshuler - Nov 15, 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Nov 15, 2021
Transactions value $
-$6,365
Form type
4
Date filed
11/16/2021, 03:04 PM
Previous filing
May 19, 2021
Next filing
Feb 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$2.62K -14 -0.04% $186.80 33.6K Nov 15, 2021 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$3.75K -20 -0.06% $187.51 33.6K Nov 15, 2021 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $186.80 (range $186.22 to $187.19).
F3 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $187.51 (range $187.26 to $187.79).